A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of a Single Oral Dose of VV261 Tablets in Chinese Healthy Volunteers
Latest Information Update: 06 Mar 2026
At a glance
- Drugs VV 261 (Primary)
- Indications Severe fever with thrombocytopenia syndrome
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Vigonvita Life Sciences
Most Recent Events
- 03 Mar 2026 Status changed from not yet recruiting to recruiting.
- 31 Dec 2025 New trial record